{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T02:55:52Z","timestamp":1772160952747,"version":"3.50.1"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Maintenance and\/or prolonged treatment with oral corticosteroid (OCS) in inflammatory bowel disease (IBD) is not recommended, yet remains common. This study assessed concomitant OCS use and overuse in IBD patients in Germany from 2017 to 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed German claims data (2017-2022). Patients over 18 years of age with continuous insurance and at least s2 quarterly diagnoses of Crohn\u2019s disease (CD) or ulcerative colitis (UC) within 2 years were included. To increase the diagnostic certainty and clinical relevance, only patients with IBD who were currently receiving any form of IBD therapy were included in the analysis. OCS overuse was defined as receiving \u22652 OCS prescriptions within 1 year alongside other IBD medications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study identified 9407 patients with confirmed CD and 11\u2005772 patients with confirmed UC who were treated with IBD medications excluding OCS monotherapy within the observation period. Among those, 42.8% of CD patients and 39.0% of UC patients were treated with concomitant OCS (CD vs. UC, P\u2005&amp;lt;\u2005.0001), while 31.3% of CD patients and 29.4% of UC patients exhibited concomitant OCS overuse (CD vs. UC, P\u2005&amp;lt;\u2005.01). Concomitant OCS use and overuse were more common among younger age groups (P\u2005&amp;lt;\u2005.01). OCS use and OCS overuse decreased significantly (P\u2005&amp;lt;\u2005.0001) from 2017 to 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study provides real-world insights into the patterns of OCS use and overuse in IBD patients. The continued reliance on OCS is highlighted, particularly in CD patients and younger age groups. Notably, steroid overuse has decreased significantly over the last 6 years.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izaf108","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T07:55:51Z","timestamp":1745394951000},"page":"2996-3002","source":"Crossref","is-referenced-by-count":1,"title":["Six-Year Observation Data Reveal Reduction in Concomitant Steroid Overuse for Inflammatory Bowel Disease in Germany"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8977-6731","authenticated-orcid":false,"given":"Ann-Sophie","family":"Stratil","sequence":"first","affiliation":[{"name":"Temedica GmbH , Munich ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2198-9925","authenticated-orcid":false,"given":"Benjamin","family":"Friedrich","sequence":"additional","affiliation":[{"name":"Temedica GmbH , Munich ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Brunner","sequence":"additional","affiliation":[{"name":"Temedica GmbH , Munich ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Rath","sequence":"additional","affiliation":[{"name":"AbbVie Deutschland GmbH & Co KG , Wiesbaden ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffeni","family":"Papukchieva","sequence":"additional","affiliation":[{"name":"Temedica GmbH , Munich ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2016-6991","authenticated-orcid":false,"given":"Bernd","family":"Bokemeyer","sequence":"additional","affiliation":[{"name":"Interdisciplinary Crohn Colitis Centre Minden , Minden ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"issue":"4","key":"2025112116473228400_CIT0001","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/ibd\/izx100","article-title":"Quality of life in inflammatory bowel disease: a systematic review and meta-analyses\u2014part I","volume":"24","author":"Knowles","year":"2018","journal-title":"Inflamm Bowel Dis."},{"issue":"8","key":"2025112116473228400_CIT0002","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1097\/MIB.0b013e318281f395","article-title":"The influence of depression on quality of life in patients with inflammatory bowel disease","volume":"19","author":"Zhang","year":"2013","journal-title":"Inflamm Bowel Dis."},{"issue":"5","key":"2025112116473228400_CIT0003","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/ibd\/izy015","article-title":"Quality of life in inflammatory bowel disease: a systematic review and meta-analyses\u2014part II","volume":"24","author":"Knowles","year":"2018","journal-title":"Inflamm Bowel Dis."},{"issue":"2","key":"2025112116473228400_CIT0004","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/j.1572-0241.2002.05475.x","article-title":"Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors","volume":"97","author":"Simr\u00e9n","year":"2002","journal-title":"Am J Gastroenterol."},{"issue":"11","key":"2025112116473228400_CIT0005","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.3109\/00365521.2014.962605","article-title":"Prevalence of inflammatory bowel disease: estimates for 2010 and trends in Germany from a large insurance-based regional cohort","volume":"49","author":"Hein","year":"2014","journal-title":"Scand J Gastroenterol."},{"key":"2025112116473228400_CIT0006","author":"Statistische \u00c4mter des Bundes und der L\u00e4nder"},{"key":"2025112116473228400_CIT0007","author":"Deutsche Gesellschaft f\u00fcr Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS)"},{"key":"2025112116473228400_CIT0008","author":"Deutsche Gesellschaft f\u00fcr Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS)"},{"issue":"1","key":"2025112116473228400_CIT0009","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis."},{"issue":"1","key":"2025112116473228400_CIT0010","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO Guidelines on therapeutics in Crohn\u2019s disease: medical treatment","volume":"14","author":"Torres","year":"2020","journal-title":"J Crohns Colitis."},{"issue":"7","key":"2025112116473228400_CIT0011","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S2468-1253(21)00065-0","article-title":"Breaking the therapeutic ceiling in drug development in ulcerative colitis","volume":"6","author":"Alsoud","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"45","key":"2025112116473228400_CIT0012","doi-asserted-by":"publisher","first-page":"768","DOI":"10.3238\/arztebl.m2023.0142","article-title":"Treatment strategies in inflammatory bowel diseases","volume":"120","author":"Stallmach","year":"2023","journal-title":"Dtsch Arztebl Int."},{"issue":"3","key":"2025112116473228400_CIT0013","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1136\/flgastro-2019-101288","article-title":"Steroid use and misuse: a key performance indicator in the management of IBD","volume":"12","author":"Blackwell","year":"2020","journal-title":"Frontline Gastroenterol"},{"issue":"3","key":"2025112116473228400_CIT0014","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/ajg.2017.479","article-title":"Increased mortality rates with prolonged corticosteroid therapy when compared with antitumor necrosis factor-\u03b1-directed therapy for inflammatory bowel disease","volume":"113","author":"Lewis","year":"2018","journal-title":"Am J Gastroenterol."},{"issue":"08","key":"2025112116473228400_CIT0015","first-page":"638","article-title":"Steroidgebrauch bei einem hohen Anteil von CED-Patienten \u2013 erste Ergebnisse aus der deutschen Kohorte der IBD-DICE-Studie","volume":"60","author":"Blumenstein","year":"2022","journal-title":"Zeitschrift f\u00fcr Gastroenterologie"},{"issue":"18","key":"2025112116473228400_CIT0016","doi-asserted-by":"publisher","first-page":"adv00309","DOI":"10.2340\/00015555-3655","article-title":"Epidemiology of Prurigo nodularis compared with psoriasis in Germany: a claims database analysis","volume":"100","author":"St\u00e4nder","year":"2020","journal-title":"Acta Derm Venereol."},{"issue":"7","key":"2025112116473228400_CIT0017","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management","volume":"11","author":"Harbord","year":"2017","journal-title":"J Crohns Colitis."},{"issue":"8","key":"2025112116473228400_CIT0018","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1007\/s00384-020-03588-w","article-title":"Indicators of active disease and steroid dependency in patients with inflammatory bowel diseases not treated with biologics in a German real-world-setting","volume":"35","author":"Bokemeyer","year":"2020","journal-title":"Int J Colorectal Dis."},{"key":"2025112116473228400_CIT0019","first-page":"KA525","article-title":"Real world evidence Daten zeigen hohe Switch-Raten von Therapiewechseln bei, advanced therapies\u201c: Eine Kassendatenanalyse der Behandlungsmuster von CED-Patienten in Deutschland","volume-title":"Zeitschrift f\u00fcr Gastroenterologie","author":"Bokemeyer","year":"2022"},{"issue":"11","key":"2025112116473228400_CIT0020","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1093\/ibd\/izab330","article-title":"Inadequate response, treatment patterns, health care utilization, and associated costs in patients with ulcerative colitis: retrospective cohort study based on German claims data","volume":"28","author":"Bokemeyer","year":"2022","journal-title":"Inflamm Bowel Dis."},{"issue":"5","key":"2025112116473228400_CIT0021","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1007\/s10620-018-5419-3","article-title":"Healthcare providers underestimate patients\u2019 glucocorticoid use in Crohn\u2019s disease","volume":"64","author":"Ghosh","year":"2019","journal-title":"Dig Dis Sci."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izaf108\/63163834\/izaf108.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/11\/2996\/63163834\/izaf108.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/11\/2996\/63163834\/izaf108.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T21:47:36Z","timestamp":1763761656000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/31\/11\/2996\/8129404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":21,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,5,13]]},"published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izaf108","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,5,13]]}}}